

HIV Infection of Naïve CD4⁺ T Cells: An Important Reservoir of Persistent HIV Infection?

Jenn Zerbato and Nicolas Sluis-Cremer*

Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, USA

A latent viral reservoir that resides in resting CD4⁺ T cells represents a major barrier to eradicating HIV infection [1-3]. This long-lived reservoir is not detectable by host immune responses and is impervious to combination antiretroviral therapy (cART) [4-6]. Consequently, there has been a major research effort to identify the cell populations that harbor latent HIV, and to develop pharmacologic approaches to specifically eradicate HIV from these cells.

In 2009, it was reported that resting central memory (T_{CM}) and transitional memory (T_{TM}) CD4⁺ T cells constituted the major latent viral reservoirs in individuals on suppressive cART [7]. Effector memory (T_{EM}) CD4⁺ T cells, and to a lesser extent naïve CD4⁺ T cells, were also found to contain integrated HIV-1 DNA, however, their overall contribution to the latent reservoir appeared to be minor. As such, recent research has largely focused on the latent HIV reservoir in CD4⁺ T_{CM} and T_{TM} cells.

Although only regarded as a minor contributor to the latent reservoir, HIV DNA is almost always detected in naïve CD4⁺ T cells in both viremic and suppressed individuals [8-17]. Earlier this year, it was reported that in some patients who received cART within 10 weeks of primary HIV infection, viremia could be controlled for at least 24 months post-treatment interruption [18]. Interestingly, in this patient population, HIV DNA could only be detected in naïve CD4⁺ T cells from 2 of 11 individuals. This suggests that the HIV reservoir in naïve CD4⁺ T cells may be more important than previously considered. Furthermore, in these patients, the short-lived T_{TM} cells and not the long-lived T_{CM} cells appeared to be the major cellular reservoir of HIV DNA [19].

The latent HIV reservoir is believed to be established early during primary infection [20-22]. In this regard, early cART administration likely reduces the size of this reservoir [23-28], and limits infection specifically in the long-lived naïve and T_{CM} CD4⁺ T cell populations. Consequently, a shorter duration of cART may be required to achieve a functional cure. This is what has been speculated in the case of the Mississippi baby, who was born HIV positive and treated 31 hours post-partum, but subsequently, became undetectable for HIV, even after treatment was stopped at 18 months [29,30]. However, from a clinical point of view, it may not always be possible to initiate cART during primary infection because many people do not know they have been infected until clinical symptoms arise, or they live in resource poor regions where access to necessary treatment is limited.

Finding a cure for HIV has become one of the biggest global challenges of the 21st century [31]. Because of the longevity of naïve CD4⁺ T cells and their ability to proliferate and differentiate upon antigen exposure into any of the memory cell subsets, as well as effector CD4⁺ T cells, they undoubtedly pose a major barrier to elimination of the latent reservoir. As such, there are several important questions that need to be addressed. Are the molecular mechanisms responsible for viral latency the same in naïve and memory CD4⁺ T cells? Are latency reversing agents, such as the histone deacetylase inhibitors vorinostat, panobinostat and romidepsin, effective in naïve CD4⁺ T cells? Does

reactivation of latent HIV infection by pharmacological agents (i.e. the kick) result in cell death in naïve CD4⁺ T cells (i.e. the kill)? To address these questions, appropriate primary cell models of HIV latency in naïve CD4⁺ T cells will have to be developed. Additionally, a greater focus on the latent reservoir in naïve CD4⁺ T cells is warranted in any clinical intervention aimed at eradicating, or reducing the size of, the latent reservoir.

References

1. Wong JK, Hezareh M, Günthard HF, Havlir DV, Ignacio CC, et al. (1997) Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. *Science* 278: 1291-1295.
2. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, et al. (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. *Science* 278: 1295-1300.
3. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, et al. (1997) Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. *Proc Natl Acad Sci U S A* 94: 13193-13197.
4. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, et al. (1999) Latent infection of CD4⁺ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. *Nat Med* 5: 512-517.
5. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, et al. (2003) Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4⁺ T cells. *Nat Med* 9: 727-728.
6. Strain MC, Günthard HF, Havlir DV, Ignacio CC, Smith DM, et al. (2003) Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: Intrinsic stability predicts lifelong persistence. *Proc Natl Acad Sci U S A* 100: 4819-4824.
7. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, et al. (2009) HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. *Nat Med* 15: 893-900.
8. Fabre-Mersseman V, Dutrieux J, Louise A, Rozlan S, Lamine A, et al. (2011) CD4⁺ recent thymic emigrants are infected by HIV *in vivo*, implication for pathogenesis. *AIDS* 25: 1153-1162.
9. Wightman F, Solomon A, Khoury G, Green JA, Gray L, et al. (2010) Both CD31(+) and CD31- naïve CD4(+) T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapy. *J Infect Dis* 202: 1738-1748.
10. Heeregrave EJ, Geels MJ, Brenchley JM, Baan E, Ambrozak DR, et al. (2009) Lack of *in vivo* compartmentalization among HIV-1 infected naïve and memory CD4⁺ T cell subsets. *Virology* 393: 24-32.

*Corresponding author: Nicolas Sluis-Cremer, Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, S817 Scaife Hall, 3550 Terrace Street, Pittsburgh, PA, 15261, USA, Tel: 1-412-648-8457; E-mail: nps2@pitt.edu

Received November 25, 2013; Accepted November 26, 2013; Published November 28, 2013

Citation: Zerbato J, Sluis-Cremer N (2013) HIV Infection of Naïve CD4⁺ T Cells: An Important Reservoir of Persistent HIV Infection? *J Antivir Antiretrovir* S10- e001. doi:10.4172/jaa.S10-e001

Copyright: © 2013 Zerbato J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

11. Brenchley JM, Hill BJ, Ambrozak DR, Price DA, Guenaga FJ, et al. (2004) T-cell subsets that harbor human immunodeficiency virus (HIV) *in vivo*: Implications for HIV pathogenesis. *J Virol* 78: 1160-1168.
12. Ostrowski MA, Chun TW, Justement SJ, Motola I, Spinelli MA, et al. (1999) Both memory and CD45RA⁺/CD62L⁺ naive CD4⁺ T cells are infected in human immunodeficiency virus type 1-infected individuals. *J Virol* 73: 6430-6435.
13. Ganesan A, Chattopadhyay PK, Brodie TM, Qin J, Gu W, et al. (2010) Immunologic and virologic events in early HIV infection predict subsequent rate of progression. *J Infect Dis* 201: 272-284.
14. Josefsson L, Palmer S, Faria NR, Lemey P, Casazza J, et al. (2013) Single cell analysis of lymph node tissue from HIV-1 infected patients reveals that the majority of CD4⁺ T-cells contain one HIV-1 DNA molecule. *PLoS Pathog* 9: e1003432.
15. Centlivre M, Legrand N, Steingrover R, van der Sluis R, Grijzen ML, et al. (2011) Altered dynamics and differential infection profiles of lymphoid and myeloid cell subsets during acute and chronic HIV-1 infection. *J Leukoc Biol* 89: 785-795.
16. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, et al. (2002) HIV preferentially infects HIV-specific CD4⁺ T cells. *Nature* 417: 95-98.
17. Baldanti F, Paolucci S, Gulminetti R, Maserati R, Migliorino G, et al. (2001) Higher levels of HIV DNA in memory and naive CD4⁺ T cell subsets of viremic compared to non-viremic patients after 18 and 24 months of HAART. *Antiviral Res* 50: 197-206.
18. Sáez-Cirión A, Bacchus C, Hocqueloux L, Avettand-Fenoël V, Girault I, et al. (2013) Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. *PLoS Pathog* 9: e1003211.
19. Bacchus C, Cheret A, Avettand-Fenoël V, Nembot G, Mélard A, et al. (2013) A single HIV-1 cluster and a skewed immune homeostasis drive the early spread of HIV among resting CD4⁺ cell subsets within one month post-infection. *PLoS One* 8: e64219.
20. Chun TW, Engel D, Berrey MM, Shea T, Corey L, et al. (1998) Early establishment of a pool of latently infected, resting CD4⁺ T cells during primary HIV-1 infection. *Proc Natl Acad Sci U S A* 95: 8869-8873.
21. Schacker T, Little S, Connick E, Gebhard-Mitchell K, Zhang ZQ, et al. (2000) Rapid accumulation of human immunodeficiency virus (HIV) in lymphatic tissue reservoirs during acute and early HIV infection: Implications for timing of antiretroviral therapy. *J Infect Dis* 181: 354-357.
22. Ghosn J, Deveau C, Chaix ML, Goujard C, Galimand J, et al. (2010) Despite being highly diverse, immunovirological status strongly correlates with clinical symptoms during primary HIV-1 infection: A cross-sectional study based on 674 patients enrolled in the ANRS CO 06 PRIMO cohort. *J Antimicrob Chemother* 65: 741-748.
23. Jain V, Hartogensis W, Bacchetti P, Hunt PW, Hatano H, et al. (2013) Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. *J Infect Dis* 208: 1202-1211.
24. Hocqueloux L, Avettand-Fenoël V, Jacquot S, Prazuck T, Legac E, et al. (2013) Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. *J Antimicrob Chemother* 68: 1169-1178.
25. Ananworanich J, Schuetz A, Vandergeeten C, Sereti I, de Souza M, et al. (2012) Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. *PLoS One* 7: e33948.
26. Schmid A, Gianella S, von Wyl V, Metzner KJ, Scherrer AU, et al. (2010) Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection. *PLoS One* 5: e13310.
27. Archin NM, Vaidya NK, Kuruc JD, Liberty AL, Wiegand A, et al. (2012) Immediate antiviral therapy appears to restrict resting CD4⁺ cell HIV-1 infection without accelerating the decay of latent infection. *Proc Natl Acad Sci U S A* 109: 9523-9528.
28. Gianella S, von Wyl V, Fischer M, Niederoest B, Battegay M, et al. (2011) Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA. *Antivir Ther* 16: 535-545.
29. Cohen J (2013) HIV/AIDS. Early treatment may have cured infant of HIV infection. *Science* 339: 1134.
30. Cohen J (2013) HIV/AIDS. Subset of CD4 cells may hold key to reaching HIV cure. *Science* 339: 1262.
31. Katlama C, Deeks SG, Autran B, Martinez-Picado J, van Lunzen J, et al. (2013) Barriers to a cure for HIV: New ways to target and eradicate HIV-1 reservoirs. *Lancet* 381: 2109-2117.

Citation: Zerbato J, Sluis-Cremer N (2013) HIV Infection of Naïve CD4⁺ T Cells: An Important Reservoir of Persistent HIV Infection? J Antivir Antiretrovir S10-e001. doi:[10.4172/jaa.S10-e001](https://doi.org/10.4172/jaa.S10-e001)

This article was originally published in a special issue, [Antiretroviral Drug Development for HIV: Challenges and Perspectives](#) handled by Editor(s), Dr. Honglin Zhou, Hospital of the University of Pennsylvania, USA

Submit your next manuscript and get advantages of OMICS Group submissions

Unique features:

- User friendly/feasible website-translation of your paper to 50 world's leading languages
- Audio Version of published paper
- Digital articles to share and explore

Special features:

- 300 Open Access Journals
- 25,000 editorial team
- 21 days rapid review process
- Quality and quick editorial, review and publication processing
- Indexing at PubMed (partial), Scopus, EBSCO, Index Copernicus and Google Scholar etc
- Sharing Option: Social Networking Enabled
- Authors, Reviewers and Editors rewarded with online Scientific Credits
- Better discount for your subsequent articles

Submit your manuscript at: <http://www.editorialmanager.com/virology>